US Stock MarketDetailed Quotes
ALXO ALX Oncology
- 2.155
- -0.025-1.15%
Trading Sep 17 14:51 ET
113.51MMarket Cap-592P/E (TTM)
2.220High2.150Low266.64KVolume2.220Open2.180Pre Close579.46KTurnover1.33%Turnover RatioLossP/E (Static)52.67MShares17.82552wk High0.71P/B43.24MFloat Cap1.88052wk Low--Dividend TTM20.06MShs Float117.450Historical High--Div YieldTTM3.21%Amplitude1.880Historical Low2.173Avg Price1Lot Size
ALX Oncology Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 16.22%-26.57M | -36.34%-37.92M | -46.11%-130.36M | -91.98%-39.68M | -0.89%-31.16M | -86.56%-31.71M | -34.55%-27.82M | -31.02%-89.22M | -18.18%-20.67M | -24.25%-30.88M |
| Net income from continuing operations | -15.34%-39.4M | -17.88%-35.58M | -30.23%-160.81M | -48.07%-45.47M | -44.37%-50.99M | -3.76%-34.16M | -23.03%-30.18M | -47.95%-123.48M | -7.99%-30.71M | -43.78%-35.32M |
| Operating gains losses | --0 | --10K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 6.28%220K | 0.47%214K | 144.44%836K | 97.14%207K | 120.00%209K | 146.43%207K | 267.24%213K | 570.59%342K | 208.82%105K | 1,483.33%95K |
| Other non cash items | 27.17%468K | 40.16%513K | 30.31%1.52M | 18.18%416K | 23.18%372K | 87.76%368K | 15.09%366K | -78.47%1.17M | -92.91%352K | 17.97%302K |
| Change In working capital | 328.81%6.21M | -148.20%-8.56M | -15.77%8.3M | -91.67%331K | 881.42%14.13M | -127.67%-2.71M | -62.26%-3.45M | 344.60%9.85M | 1,393.61%3.97M | 61.88%-1.81M |
| -Change in prepaid assets | 26.77%-1.56M | -2,749.41%-4.5M | 12.53%-1.29M | 165.52%3.02M | 2.90%-2.35M | -254.45%-2.13M | 110.78%170K | 11.19%-1.48M | 199.21%1.14M | -59.96%-2.42M |
| -Change in payables and accrued expense | 355.65%6.47M | 22.39%-3.57M | -8.47%10.58M | -73.11%527K | 1,990.51%17.18M | -129.08%-2.53M | -7,183.08%-4.6M | 44.14%11.55M | 16.95%1.96M | 159.18%822K |
| -Change in other current assets | -21.44%1.77M | -87.34%149K | 82.13%1.37M | -380.14%-2.85M | 1,449.02%790K | 224,900.00%2.25M | 471.29%1.18M | 107.75%750K | 4.74%1.02M | 103.16%51K |
| -Change in other current liabilities | -57.24%-467K | -229.84%-630K | -140.84%-2.35M | -159.57%-366K | -467.80%-1.5M | -7.61%-297K | 35.47%-191K | -39.97%-977K | 94.89%-141K | -15.79%-264K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 16.22%-26.57M | -36.34%-37.92M | -46.11%-130.36M | -91.98%-39.68M | -0.89%-31.16M | -86.56%-31.71M | -34.55%-27.82M | -31.02%-89.22M | -18.18%-20.67M | -24.25%-30.88M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -85.40%907K | -37.41%26.47M | 118.97%44.66M | -252.31%-16.67M | -6.43%12.82M | 108.16%6.21M | 123.00%42.3M | -4,681.96%-235.42M | 342.19%10.94M | 3,540.95%13.7M |
| Net PPE purchase and sale | 94.82%-90K | 78.55%-148K | 10.72%-1.27M | 61.95%-148K | 778.65%1.3M | -576.65%-1.74M | -17.15%-690K | -114.26%-1.43M | -49.04%-389K | 51.76%-192K |
| Net intangibles purchase and sale | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Net investment purchase and sale | -87.46%997K | -38.07%26.62M | 119.63%45.93M | -245.78%-16.52M | -17.10%11.51M | 110.48%7.95M | 123.45%42.99M | ---233.99M | --11.33M | --13.89M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -85.40%907K | -37.41%26.47M | 118.97%44.66M | -252.31%-16.67M | -6.43%12.82M | 108.16%6.21M | 123.00%42.3M | -4,681.96%-235.42M | 342.19%10.94M | 3,540.95%13.7M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 7,816.03%27.15M | 2,984.11%3.09M | 501.33%59.29M | 523.19%59.17M | 18.38%-111K | -18.72%343K | -233.75%-107K | 298.87%9.86M | 1,711.83%9.49M | -130.98%-136K |
| Net issuance payments of debt | -103.74%-218K | -63.55%-175K | -104.04%-388K | -100.64%-63K | 21.28%-111K | -205.71%-107K | -1.90%-107K | 3,520.64%9.61M | 9,612.50%9.89M | -35.58%-141K |
| Net common stock issuance | --26.2M | --3.02M | --58.89M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | 159.33%1.17M | --237K | -12.29%792K | 33.59%342K | --0 | -1.53%450K | --0 | -67.20%903K | -59.24%256K | -99.08%5K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---655K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 7,816.03%27.15M | 2,984.11%3.09M | 501.33%59.29M | 523.19%59.17M | 18.38%-111K | -18.72%343K | -233.75%-107K | 298.87%9.86M | 1,711.83%9.49M | -130.98%-136K |
| Net cash flow | ||||||||||
| Beginning cash position | -77.70%14.11M | -54.03%22.47M | -86.56%48.89M | -60.00%19.65M | -42.65%38.11M | -60.25%63.26M | -86.56%48.89M | -16.25%363.67M | -87.25%49.12M | -83.79%66.44M |
| Current changes in cash | 105.94%1.49M | -158.20%-8.37M | 91.61%-26.42M | 1,316.38%2.82M | -6.53%-18.46M | 72.87%-25.16M | 107.03%14.37M | -346.17%-314.78M | 98.92%-232K | 30.19%-17.32M |
| End cash Position | -59.06%15.6M | -77.70%14.11M | -54.03%22.47M | -54.03%22.47M | -60.00%19.65M | -42.65%38.11M | -60.25%63.26M | -86.56%48.89M | -86.56%48.89M | -87.25%49.12M |
| Free cash flow | 20.31%-26.66M | -33.56%-38.07M | -45.22%-131.64M | -89.13%-39.83M | 3.92%-29.86M | -93.86%-33.45M | -34.06%-28.51M | -24.14%-90.65M | 4.31%-21.06M | -23.05%-31.08M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data